Alcon Inc. — FY2021 Form 20-F
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone Q4 report; the filing does not provide a clear set of Q4-only financial results. Financial statements are prepared under IFRS in U.S. dollars.
Business context and results
Alcon develops and sells ophthalmic products through Surgical and Vision Care. Surgical includes cataract, vitreoretinal, refractive and glaucoma products; Vision Care includes contact lenses and ocular health products. The company reported net sales of $8.222 billion and described itself as a global eye-care market leader.
| Metric | FY2021 | FY2020 | Change / context |
|---|---|---|---|
| Net sales to third parties | $8.222B | $6.763B | +22% reported; +20% at constant currencies |
| Gross profit | $4.652B | $2.940B | Gross margin approximately 56.6%, versus 43.5% |
| Operating income (loss) | $580M | $(482)M | Operating margin 7.1%, versus (7.1)% |
| Net income (loss) | $376M | $(531)M | Basic EPS $0.77; diluted EPS $0.76 |
| Core operating income | $1.443B | $789M | +83% reported; core operating margin 17.6%, versus 11.7% |
| Core net income | $1.063B | $512M | Core diluted EPS $2.15, versus $1.04 |
| Operating cash flow | $1.345B | $823M | Increased $522M |
| Free cash flow | $645M | $350M | Non-IFRS measure; after $700M of property, plant and equipment purchases |
Segment sales: Surgical generated $4.703B, up 27% reported and 25% at constant currencies; Vision Care generated $3.519B, up 15% and 14%, respectively. Surgical segment contribution was $1.184B (25.2% of segment sales); Vision Care contribution was $604M (17.2%). Both businesses benefited from recovery versus pandemic-affected 2020. The U.S. represented 44% of sales.
Liquidity, debt and investment
At year-end, cash and cash equivalents were $1.575B, total financial debt was $4.080B and net debt was $2.499B, down from $2.558B a year earlier. The $1B revolving credit facility was undrawn; the company reported no major debt maturities before 2024 and no financial covenants. Average debt maturity was 8.0 years. Cash and debt levels were broadly stable year over year.
Investing cash outflow was $1.198B, including higher capital spending and the $355M purchase of U.S. commercialization rights to Simbrinza. Capital expenditures were $700M, compared with $479M in 2020. The company reported $186M of property, plant and equipment purchase commitments at year-end. Ivantis was acquired after year-end on January 7, 2022; cash paid, net of cash acquired, was $475M, with additional contingent milestone payments possible.
Material changes, outlook and risks
- Recovery and growth: Sales exceeded 2020 and were 12% above 2019, which the company characterized as a pre-COVID comparison. Recovery was strongest in the U.S.; international markets recovered at varying rates. Growth reflected surgical procedure recovery, product launches and adoption of advanced technology lenses.
- Costs and unusual items: IFRS operating income included $225M of intangible-asset impairment charges. Core operating income excludes specified items, including amortization, impairments, transformation costs, separation costs and legal items; it is a non-IFRS measure and should not be treated as a substitute for IFRS results. R&D spending rose to $842M from $673M.
- Management outlook: The filing does not give a clear company-wide FY2022 revenue or earnings forecast. Management expected some lingering COVID-19 effects through mid-2022 and said supply-chain challenges and inflation in components, freight, labor, resins and plastics were expected to continue through 2022 and could pressure operating margin despite pricing and productivity actions. Alcon cited mid-single-digit annual growth expectations for its served markets from 2021 to 2026; this is market context, not company guidance.
- Legal and compliance: Alcon remained subject to a three-year Deferred Prosecution Agreement with the U.S. Department of Justice, entered in June 2020; Novartis indemnified the $8.925M penalty. Breach could lead to renewed prosecution or other sanctions. Contact-lens antitrust class actions, a J&J patent and copyright dispute involving LenSx, and a Hoya patent case involving UltraSert remained pending; disclosed trial dates were in 2022 and 2023.
- Other exposures: The company disclosed a CHF260M potential Swiss tax-incentive clawback obligation at year-end, scheduled to expire December 31, 2022 if requirements are met. Additional risks include supply constraints (including semiconductor chips), COVID-related demand disruption, pricing and reimbursement pressure, foreign-exchange movements, regulatory approvals, product liability and impairment risk. A 1% U.S. dollar movement against its currency basket was estimated to change annual sales by $43M and operating income by $18M.
- Dividend: Alcon paid its first dividend in May 2021, CHF0.10 per share ($54M). The Board proposed CHF0.20 per share for shareholder approval in 2022; payment was not assured until approved.
Important facts for investors to verify
- Compare subsequent reported results with the 2021 recovery baseline, including the pace of international recovery and whether sales growth translated into sustainable operating margins.
- Review the reconciliation of core results to IFRS, especially the $225M impairment and other excluded costs, and assess whether core earnings better reflect recurring performance.
- Monitor free cash flow, capital spending, working-capital needs, net debt and the funding and returns expected from manufacturing expansions and acquisitions.
- Check the outcome and financial implications of the pending antitrust and patent litigation, and confirm completion of the DOJ agreement without breach.
- Verify progress on supply availability and cost inflation, the Swiss tax-incentive requirements through expiry, and shareholder approval and payment of the proposed dividend.